Manchester Score for Prognosis in Small Cell Lung Cancer

ورودی‌های بالینی بیمار

حداقل ۱۱۰ — حداکثر ۱۶۰ • واحد: mmol/L

حداقل ۱۰ — حداکثر ۴۰ • واحد: mmol/L

حداقل ۰ — حداکثر ۱۰۰ • واحد: points

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
manchester score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Good Prognosis0–1
  • Medium Prognosis2–3
  • Poor Prognosis4–6
Direct Clinical Answer

The Manchester Score for Prognosis in Small Cell Lung Cancer calculator is designed for bedside predicting 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters in clinical practice. The resulting score directly guides clinician decision-making regarding determining appropriate.

Clinical Guidelines & Evidence

Predicts 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters. Stratifies patients into three prognostic groups (good, medium, poor) to guide treatment decisions and clinical management.

Clinical Indication

The Manchester Score for Prognosis in Small Cell Lung Cancer is indicated for bedside clinical practice to support Predicts 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters. Stratifies patients into three prognostic groups (good, medium, poor) to guide treatment decisions and clinical management.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with community-acquired pneumonia, COPD exacerbations, acute asthma, pulmonary embolism, or acute respiratory distress. Clinical application is indicated across Respiratory care units, emergency pulmonary triage, sleep clinics, and medical floors.

Limitations & Contraindications

Peripheral pulse oximetry loses reliability in hypoperfusion, severe vasoconstriction, methemoglobinemia, or carboxyhemoglobinemia.

Clinical Pearls & Action Plan

Synchronous evaluation of arterial blood gas (PaO2/FiO2), mechanics of breathing, and clinical trajectory guides respiratory failure management. Guideline pearl: 61 pre-treatment variables were initially evaluated through multiple regression analysis.

Formula & Variables:

Manchester Score = LDH points + Sodium points + Alkaline Phosphatase points + Bicarbonate points + Disease Stage points + Karnofsky Performance Status points. LDH >ULN (1 point), Na <132 mmol/L (1 point), ALP >1.5x ULN (1 point), HCO3 <24 mmol/L (1 point), Extensive stage (1 point), KPS ≤50 (1 point). Total score 0-1 = Good prognosis, 2-3 = Medium prognosis, 4-6 = Poor prognosis.

Input Parameters

NameTypeRequiredDescription
serum_ldhstringYesSerum lactate dehydrogenase level relative to upper limit of normal. Elevated LDH reflects increased tumor burden and metabolic activity, indicating worse prognosis
serum_sodiumfloatYesSerum sodium concentration in mmol/L. Hyponatremia (<132 mmol/L) often results from SIADH (syndrome of inappropriate antidiuretic hormone secretion) commonly associated with SCLC(mmol/L)
serum_alkaline_phosphatasestringYesSerum alkaline phosphatase level relative to upper limit of normal. Elevated ALP (>1.5x normal) suggests liver or bone metastases, indicating extensive disease
serum_bicarbonatefloatYesSerum bicarbonate concentration in mmol/L. Low bicarbonate (<24 mmol/L) may indicate metabolic acidosis associated with advanced disease or organ dysfunction(mmol/L)
disease_stagestringYesSmall cell lung cancer staging. Limited stage: confined to one hemithorax including ipsilateral hilar and supraclavicular nodes. Extensive stage: disease beyond limited stage boundaries
karnofsky_performance_statusintegerYesKarnofsky Performance Status scale (0-100). Measures functional status and ability to carry out activities of daily living. Lower scores indicate worse functional status and prognosis(points)

Score Interpretation & Guidance

RangeStageDescription
0–1Good PrognosisGood prognostic group with best survival outcomes
2–3Medium PrognosisIntermediate prognostic group with moderate survival outcomes
4–6Poor PrognosisPoor prognostic group with worst survival outcomes

Evidence-Based References (EBM)

  • Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Jul 15;40(1):1-7. doi: 10.1002/ijc.2910400102.DOI: 10.1002/ijc.2910400102
  • Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221.DOI: 10.1200/JCO.1995.13.5.1221
  • Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990 Sep;8(9):1563-74. doi: 10.1200/JCO.1990.8.9.1563.DOI: 10.1200/JCO.1990.8.9.1563

Related calculators